Or, for some of it, many enjoyable minutes. (g)

I was looking up Provenge again and found a link to this:

++++++++++++++++++

Cell Genesys, Inc. (Cell Genesys), incorporated in 1988, is a
biotechnology company focused on the development and commercialization
of biological therapies for patients with cancer. Its clinical stage
cancer programs involve cell- or viral-based products that have been
genetically modified to impart disease-fighting characteristics that
are not found in conventional chemotherapeutic agents. The Company's
lead program is GVAX cell-based immunotherapy for cancer. As of
December 31, 2006, it was conducting two Phase lll clinical trials in
prostate cancer and Phase ll trials in each of pancreatic cancer and
leukemia. Cell Genesys initiated its Phase lll clinical trials for
GVAX immunotherapy for prostate cancer in July 2004 and June 2005,
each under a special protocol assessment (SPA) with the United States
Food and Drug Administration (FDA). In its oncolytic virus therapies
program, which the Company (as of December 31, 2006) was developing in
part through a global alliance with Novartis AG (Novartis), it
initiated a Phase 1 clinical trial of CG0070 in recurrent bladder
cancer in April 2005. It expanded the CG0070 Phase 1 trial to evaluate
escalating multiple-dose regimens during the year ended December 31,
2006. The Company also has other preclinical oncolytic virus therapy
programs, including CG5757, which it is evaluating as potential
therapies for multiple types of cancer.

GVAX Cancer Immunotherapy Program

The Company's GVAX immunotherapies are cancer treatments designed to
stimulate the patient's immune system to effectively fight cancer.
GVAX cancer immunotherapies are comprised of tumor cells that are
genetically modified to secrete an immune-stimulating cytokine known
as granulocyte-macrophage colony-stimulating factor (GM-CSF), and are
then irradiated for safety.

As of December 31, 2006, more than 600 patients had received Cell
Genesys' GVAX cancer immunotherapies in multiple Phase 1 and ll
clinical trials to date, and the immunotherapies have been shown to
have a favorable side effect profile that avoids many of the
toxicities associated with conventional cancer therapies. GVAX cancer
immunotherapies can be administered in an outpatient setting as an
injection into the skin, a site where immune cells, including in
particular dendritic cells, can be optimally accessed and activated.
As of December 31, 2006, the Company's GVAX cancer immunotherapies was
being tested as non patient-specific, or allogeneic, products.

The Company's GVAX immunotherapy for prostate cancer is a non patient-
specific product comprised of two genetically-modified prostate cancer
cell lines. It has completed five Phase 1 and Phase ll clinical trials
of its GVAX immunotherapy for prostate cancer in approximately 200
patients with various stages of recurrent prostate cancer, and the
immunotherapy has had a favorable safety profile in each trial. These
clinical trials include two Phase ll clinical trials in hormone-
refractory prostate cancer patients with radiologic evidence of
metastatic (spreading) disease (metastatic HRPC), which is the target
population for its Phase lll trials.

Cell Genesys' GVAX immunotherapy for pancreatic cancer is a non
patient-specific product. As of December 31, 2006, a Phase ll clinical
trial of GVAX immunotherapy for pancreatic cancer was being conducted
by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in
60 patients with resectable pancreatic cancer who received the
immunotherapy after surgical resection of their tumor and standard
adjuvant radiation and chemotherapy. Its GVAX cancer immunotherapy for
leukemia is a non patient-specific GVAX cancer immunotherapy product.

++++++++++++++++++++++

http://www.investor.reuters.wallst.com/stocks/company-profile.asp?rpc=66&ticker=
CEGE.O

So, best I can tell, there are several silver bullets being loaded.
Probably not all treatments will work for everyone but each new
treatment is another chance for each us.

The trick is to, er, like a girlfriend told me 35 years ago, "Hang on,
for the ride of your life."

-kh How am I going to explain these teethmarks?